300841.SZ
康华生物
SZSE · Healthcare · C 制造业 · CN
CNY 53.27
−5.72%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
17.6x
Market Cap
CNY 6.92B
MomentumView details →
1D Return
−5.72%
YTD Return
−29.50%
RSI (14)
50.1
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
17.6x
Market Cap
CNY 6.92B
RSI (14)
50.1
MomentumView details →
1D Return
−5.72%
YTD Return
−29.50%
Similar companies
Latest newsMore news →
Kanghua Biological announced its first-half 2026 results: revenue of 538 million yuan, up 11.25% year-on-year; net profit attributable to shareholders of 141 million yuan, up 23.25% year-on-year; non-recurring-adjusted net profit of 134 million yuan, up 20.28% year-on-year. The company plans no cash dividend, no bonus shares, and no capital reserve conversion.18d agoKanghua Biotech announced that its external investment and related-party transaction proposal was approved at an extraordinary shareholders' meeting, planning to subscribe in installments to Namixin's newly increased registered capital and acquire equity, holding 100% of Namixin after completion; recently Namixin completed the first-phase industrial and commercial change registration with a registered capital of 27.17 million yuan.32d ago